Resumo

REIS, Joel; RAPOSO, Inês  e  SELORES, Manuela. Dupilumab for recalcitrant prurigo nodularis: Case report. Port J Dermatol Venereol. [online]. 2022, vol.80, n.1, pp.56-59.  Epub 16-Maio-2022. ISSN 2795-501X.  https://doi.org/10.24875/pjd.m22000010.

Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. We present a case of recalcitrant prurigo nodularis treated off-label with dupilumab.

Palavras-chave : Antibodies; Monoclonal; Humanized; Dupilumab; Prurigo/drug therapy.

        · resumo em Português     · texto em Inglês     · Inglês ( pdf )